Tumors without expression of ER, PR, and overexpression of HER2, collectively known as triple-negative breast cancer (TNBC), lack targeted therapies, leaving chemotherapy as the only systemic therapeutic alternative (2). Here, ERBB2 is linked to triple-negative breast carcinoma.